StemCells (NASDAQ: STEM) announced that the six-month interim results for the first cohort in its ongoing Phase II Pathway™ Study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE